Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SII Inactivated Salk Polio Vaccine
- Development stage
- Phase 3
- Lead developer
- Serum Institute of India
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**SII Inactivated Salk Polio Vaccine** is Serum Institute of India's adsorbed, reduced-dose trivalent inactivated poliovirus vaccine for prevention of poliomyelitis caused by poliovirus types 1, 2, and 3. Each 0.5 mL dose contains inactivated poliovirus type 1 Mahoney strain, type 2 MEF-1 strain, and type 3 Saukett strain, produced in Vero cells and adsorbed to aluminum hydroxide. It induces neutralizing humoral immunity against the three poliovirus serotypes and was evaluated in a completed randomized Phase III infant study assessing immunogenicity, safety, and lot-to-lot consistency. ([cdsco.gov.in](https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCTApprovals/8_SERUM_IPV.pdf))
- Brand names
- Poliovac
- Other names
- SII Inactivated Salk Polio Vaccine (Adsorbed)Inactivated Salk Polio Vaccine (Adsorbed)
Beyond the preview
Go deeper on SII Inactivated Salk Polio Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SII Inactivated Salk Polio Vaccine.